Technical Analysis for NERV - Minerva Neurosciences, Inc

Grade Last Price % Change Price Change
F 2.62 9.39% 0.23
NERV closed up 9.39 percent on Friday, November 1, 2024, on 7.37 times normal volume. It ran into resistance at its 50 day moving average.
Earnings due: Nov 5
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
Bullish Engulfing Bullish 0.00%
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Outside Day Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 20 hours ago
Rose Above Previous Day's High about 20 hours ago
Rose Above 10 DMA about 20 hours ago
Outside Day about 20 hours ago
Up 5% about 20 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Minerva Neurosciences, Inc Description

Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Neuroscience Parkinson's Disease Psychoactive Drugs Schizophrenia Major Depressive Disorder Depressive Disorder Treatment Of Parkinson's Disease Neurochemistry Antidepressants Ketones Insomnia Treatment Of Major Depressive Disorder Central Nervous System Disease Investigational New Drug Treatment Of Central Nervous System Diseases

Is NERV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.49
52 Week Low 2.26
Average Volume 14,440
200-Day Moving Average 3.55
50-Day Moving Average 2.66
20-Day Moving Average 2.55
10-Day Moving Average 2.48
Average True Range 0.14
RSI (14) 53.05
ADX 18.02
+DI 29.27
-DI 13.69
Chandelier Exit (Long, 3 ATRs) 2.41
Chandelier Exit (Short, 3 ATRs) 2.73
Upper Bollinger Bands 2.73
Lower Bollinger Band 2.37
Percent B (%b) 0.69
BandWidth 14.13
MACD Line -0.06
MACD Signal Line -0.06
MACD Histogram 0.0057
Fundamentals Value
Market Cap 18.32 Million
Num Shares 6.99 Million
EPS -4.67
Price-to-Earnings (P/E) Ratio -0.56
Price-to-Sales 1.87
Price-to-Book 2.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.40
Resistance 3 (R3) 3.38 3.11 3.27
Resistance 2 (R2) 3.11 2.91 3.12 3.23
Resistance 1 (R1) 2.86 2.79 2.99 2.88 3.18
Pivot Point 2.59 2.59 2.65 2.60 2.59
Support 1 (S1) 2.34 2.39 2.47 2.36 2.06
Support 2 (S2) 2.07 2.27 2.08 2.01
Support 3 (S3) 1.82 2.07 1.97
Support 4 (S4) 1.84